Product Name: CDKL5 (168-174) pY171
Product Number: PE-04ACN90
Size: 200 µg      Price:41.00
1 mg      $US82.00
5 mg      194.00
Peptide Name: CDKL5 (168-174) pY171

Product Use: Services as a blocking peptide for use with the CDKL5-pY171 rabbit polyclonal antibody (Cat. No.: AB-PK576) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y171 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: YTE-pY-VAT

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1100.06 Da

Peptide Purity Percent after Synthesis and Purification: 90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: CDKL5 - pY171 phosphosite-specific antibody (Cat. No.: AB-PK576)

Scientific Background: CDKL5 is a protein-serine/threonine kinase of the CMGC group and CDKL family. It is likely that phosphorylation at Y24 is inhibitory and phosphorylation at Y171 is required for catalytic activity based on homology with other CDK's. It has been reported to phosphorylate MECP2. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis. It has also been linked with Rett Syndrome, which is a neuro-development disorder affecting psychomotor development, autistic like features, seizures, and slow head growth. Rett Syndrome is also associated with neuroblastomas.